Universal Biosensors surges 60% on FDA approval for Class II device
Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical Laboratory Improvement Amendments Waiver approvals.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
GNE | Ann: ASX 3A.1 Notification of dividend | 22/02/24 | 0 | 69 | |||
|
|||||||
GNE | Ann: Genesis meets expectations in challenging environment | 22/02/24 | 0 | 157 | |||
|
|||||||
GNE | Ann: H1 FY24 Conference Call Details | 16/02/24 | 0 | 99 | |||
|
|||||||
GNE | Ann: Resignation of Chief Financial Officer | 16/02/24 | 0 | 102 | |||
|
|||||||
GNE | Ann: FY24 Q2 Performance Report | 22/01/24 | 0 | 128 | |||
|
|||||||
GNE | Ann: Lauriston Solar Farm | 22/12/23 | 0 | 94 | |||
|
|||||||
GNE | Ann: D&O Ongoing Disclosure Notice | 22/12/23 | 0 | 74 | |||
|
|||||||
GNE | Ann: H1 FY24 Results Announcement Date | 11:21 | 0 | 81 | |||
|
See All Discussions